# Editas Medicine Inc. (EDIT) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $3.23, market value $496 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Editas Medicine Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 10.6×**. Each dollar of revenue is priced at 10.6×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 4.7×**. The shares trade at 4.7× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -24.3%** (5-yr avg -71.6%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Operating margin: -161.4%**. Operating margin is negative: the business loses money before interest and tax.
- **Net margin: -395.0%**. The company reported a net loss over the last twelve months.
- **Return on equity: -586.6%**. Return on equity is negative because earnings are negative.
- **Return on invested capital: 98.6%**. Return on all capital, debt included, is 98.6%: comfortably above what that capital costs.
- **Return on assets: -39.6%**. Each dollar of assets produces -39.6% of profit.

## Growth
- **Revenue growth (1 yr): 25.4%** (3-yr 27.1%/yr, 5-yr -14.9%/yr). Revenue grew 25.4% over the last year, against -14.9% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 37.5%**. Earnings per share rose 37.5%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Debt to equity: 2.15**. Debt is 2.15 times equity, a leveraged balance sheet that needs steady cash flow to service.
- **Altman Z-score: -0.54**. A Z-score of -0.54 is in the distress zone, a signal to examine the balance sheet closely.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Editas Medicine Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: buy** (9 analysts). 9 analysts cover Editas Medicine Inc.; the consensus is buy, with an average price target of $6.00 (+86% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 28.2%** (YTD 57.6%, 3-mo 19.2%). The shares are up 28.2% over twelve months including dividends.
- **From 52-week high: -28.8%** (94.6% above the low). Trading 29% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 57**. An RSI of 57 is neutral.
- **Beta (1 yr): 2.12** (volatility 85%). Beta of 2.12 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=EDIT · Page: https://foliofundamentals.com/stocks/edit

Not investment advice.